Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
Despite recent advances in novel therapies, the prognosis for patients with squamous cell
carcinoma of the head and neck (SCCHN) remains poor. Progress in understanding the …
carcinoma of the head and neck (SCCHN) remains poor. Progress in understanding the …
Targeting PI3K signaling in combination cancer therapy
Targeting upstream phosphatidylinositol-3-kinases (PI3Ks) in the PI3K/Akt/mTOR pathway
appears to be a promising therapy in solid cancers; however, first early clinical trials with …
appears to be a promising therapy in solid cancers; however, first early clinical trials with …
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-and ErbB family-targeted agents in the treatment of head and neck …
RB Cohen - Cancer treatment reviews, 2014 - Elsevier
Overexpression of the epidermal growth factor receptor (EGFR) is a common characteristic
of head and neck squamous cell carcinomas (HNSCC). Cetuximab is a chimeric anti-EGFR …
of head and neck squamous cell carcinomas (HNSCC). Cetuximab is a chimeric anti-EGFR …
[HTML][HTML] N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines
X Zhang, G Liu, Y Kang, Z Dong, Q Qian, X Ma - PloS one, 2013 - journals.plos.org
Background The epidermal growth-factor receptor tyrosine kinase inhibitors have been
effective in non-small cell lung cancer patients. However, acquired resistance eventually …
effective in non-small cell lung cancer patients. However, acquired resistance eventually …
[HTML][HTML] Precision medicine approaches to overcome resistance to therapy in head and neck cancers
S Ortiz-Cuaran, J Bouaoud, A Karabajakian… - Frontiers in …, 2021 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …
[HTML][HTML] Combination therapy as a promising way to fight oral cancer
Oral cancer is a highly aggressive tumor with invasive properties that can lead to metastasis
and high mortality rates. Conventional treatment strategies, such as surgery, chemotherapy …
and high mortality rates. Conventional treatment strategies, such as surgery, chemotherapy …
STAT3/HOTAIR signaling axis regulates HNSCC growth in an EZH2-dependent manner
S Sun, Y Wu, W Guo, F Yu, L Kong, Y Ren, Y Wang… - Clinical Cancer …, 2018 - AACR
Abstract Purpose: PI3K and STAT3 are frequently activated in cancer progression. However,
little is known about the underlying mechanisms by which PI3K and STAT3 regulate head …
little is known about the underlying mechanisms by which PI3K and STAT3 regulate head …
Anti‐epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance
C Boeckx, M Baay, A Wouters, P Specenier… - The …, 2013 - academic.oup.com
Targeted therapy against the epidermal growth factor receptor (EGFR) is one of the most
promising molecular therapeutics for head and neck squamous cell carcinoma (HNSCC) …
promising molecular therapeutics for head and neck squamous cell carcinoma (HNSCC) …
[HTML][HTML] A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma …
Background An open-label, multicenter, single-arm phase II trial was conducted to
investigate the clinical activity of dacomitinib in recurrent/metastatic squamous-cell …
investigate the clinical activity of dacomitinib in recurrent/metastatic squamous-cell …
[HTML][HTML] The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
V D'amato, R Rosa, C D'amato, L Formisano… - British journal of …, 2014 - nature.com
Background: Cetuximab is the only targeted agent approved for the treatment of head and
neck squamous cell carcinomas (HNSCC), but low response rates and disease progression …
neck squamous cell carcinomas (HNSCC), but low response rates and disease progression …